These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 2285297)
1. Comparative in vitro activities of newer quinolones against Pseudomonas species and Xanthomonas maltophilia isolated from patients with cancer. Rolston KV; Messer M; Ho DH Antimicrob Agents Chemother; 1990 Sep; 34(9):1812-3. PubMed ID: 2285297 [TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibility of Xanthomonas (Pseudomonas) maltophilia to newer antimicrobial agents. Khardori N; Reuben A; Rosenbaum B; Rolston K; Bodey GP Antimicrob Agents Chemother; 1990 Aug; 34(8):1609-10. PubMed ID: 2221872 [TBL] [Abstract][Full Text] [Related]
3. Comparative in-vitro susceptibilities of Pseudomonas aeruginosa, Xanthomonas maltophilia, and Pseudomonas spp. to sparfloxacin (CI-978, AT-4140, PD131501) and reference antimicrobial agents. Louie A; Baltch AL; Ritz WJ; Smith RP J Antimicrob Chemother; 1991 Jun; 27(6):793-9. PubMed ID: 1657857 [TBL] [Abstract][Full Text] [Related]
4. Susceptibility of Xanthomonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selected in vitro. Lecso-Bornet M; Pierre J; Sarkis-Karam D; Lubera S; Bergogne-Berezin E Antimicrob Agents Chemother; 1992 Mar; 36(3):669-71. PubMed ID: 1622183 [TBL] [Abstract][Full Text] [Related]
5. Susceptibility of Xanthomonas maltophilia and amikacin-resistant gram-negative bacteria to newer antimicrobials. Matsuyama JR; Beail B; Wallis C; Zeleznik D; Tartaglione T Clin Pharm; 1991 Jul; 10(7):544-8. PubMed ID: 1860303 [TBL] [Abstract][Full Text] [Related]
6. In-vitro susceptibilities of Pseudomonas aeruginosa and Pseudomonas spp. to the new fluoroquinolones clinafloxacin and PD 131628 and nine other antimicrobial agents. Ford AS; Baltch AL; Smith RP; Ritz W J Antimicrob Chemother; 1993 Apr; 31(4):523-32. PubMed ID: 8390434 [TBL] [Abstract][Full Text] [Related]
7. Antibiotic susceptibility profile of Xanthomonas maltophilia. In vitro activity of beta-lactam/beta-lactamase inhibitor combinations. García-Rodríguez JA; García Sánchez JE; García García MI; García Sánchez E; Muñoz Bellido JL Diagn Microbiol Infect Dis; 1991; 14(3):239-43. PubMed ID: 1889176 [TBL] [Abstract][Full Text] [Related]
8. Antimicrobial interactions of trovafloxacin and extended-spectrum cephalosporins or azithromycin tested against clinical isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia. Johnson DM; Jones RN; Pfaller MA J Antimicrob Chemother; 1998 Oct; 42(4):557-9. PubMed ID: 9818765 [No Abstract] [Full Text] [Related]
9. In vitro activity of sparfloxacin compared with those of five other quinolones. Cantón E; Pemán J; Jimenez MT; Ramón MS; Gobernado M Antimicrob Agents Chemother; 1992 Mar; 36(3):558-65. PubMed ID: 1320362 [TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro activity of gatifloxacin against Stenotrophomonas maltophilia and Burkholderia species isolates including evaluation of disk diffusion and E test methods. Biedenbach DJ; Croco MA; Barrett TJ; Jones RN Eur J Clin Microbiol Infect Dis; 1999 Jun; 18(6):428-31. PubMed ID: 10442421 [TBL] [Abstract][Full Text] [Related]
11. In vitro activities of the newer beta-lactam and quinolone antimicrobial agents against Pseudomonas pseudomallei. Ashdown LR Antimicrob Agents Chemother; 1988 Sep; 32(9):1435-6. PubMed ID: 3196005 [TBL] [Abstract][Full Text] [Related]
12. The in-vitro activity of temafloxacin compared with other antimicrobial agents. King A; Bethune L; Phillips I J Antimicrob Chemother; 1991 Jun; 27(6):769-79. PubMed ID: 1657855 [TBL] [Abstract][Full Text] [Related]
13. In vitro activity of lomefloxacin, a difluorinated quinolone, compared with other antimicrobials. Qadri SM; Lee GC; Ellis ME Chemotherapy; 1991; 37(3):166-74. PubMed ID: 1889304 [TBL] [Abstract][Full Text] [Related]
14. Temafloxacin: in vitro comparison with five other antibacterial agents. Digranes A; Hardardottir H; Bottolfsen KL Chemotherapy; 1991; 37(2):98-105. PubMed ID: 2032475 [TBL] [Abstract][Full Text] [Related]
15. Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin. Pankuch GA; Jacobs MR; Appelbaum PC Antimicrob Agents Chemother; 1994 Feb; 38(2):369-70. PubMed ID: 8192468 [TBL] [Abstract][Full Text] [Related]
16. In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone. Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N Chemotherapy; 1992; 38(2):99-106. PubMed ID: 1317282 [TBL] [Abstract][Full Text] [Related]
17. In vitro activity of temafloxacin hydrochloride (TA-167 or A-62254), a new fluorinated 4-quinolone. Nakanishi N; Inoue M; Inoue K; Yamaguchi T; Mitsuhashi S Chemotherapy; 1990; 36(5):345-55. PubMed ID: 2209168 [TBL] [Abstract][Full Text] [Related]
18. In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. Cooper MA; Andrews JM; Ashby JP; Matthews RS; Wise R J Antimicrob Chemother; 1990 Nov; 26(5):667-76. PubMed ID: 2079449 [TBL] [Abstract][Full Text] [Related]
19. Comparative in vitro activity of the new difluoro-quinolone temafloxacin (A-62254) against bacterial isolates from cancer patients. Rolston KV; Ho DH; LeBlanc B; Gooch G; Bodey GP Eur J Clin Microbiol Infect Dis; 1988 Oct; 7(5):684-6. PubMed ID: 3143585 [TBL] [Abstract][Full Text] [Related]
20. In-vitro activities of temafloxacin, tosufloxacin (A-61827) and five other fluoroquinolone agents. Barry AL; Jones RN J Antimicrob Chemother; 1989 Apr; 23(4):527-35. PubMed ID: 2745259 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]